Exploring exercise prescription parameters for pregnancy-related pelvic girdle pain: A systematic review and meta-analysis of effects on pain and function.

J PainAug 4, 2026 (epub)
Clinical ResearchObstetrics & GynecologyPhysical Medicine & Rehabilitation

Xiaohui Lu, Dan Zhou, Junlan Shi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of exercise interventions on pain and function in pregnant individuals with pelvic girdle pain (PGP). Analyzing 11 randomized controlled trials with 810 participants, the study found that exercise significantly reduced pain (SMD: -0.81) and improved function (SMD: -0.69).

Key findings

  • Exercise interventions significantly reduced pain with a standardized mean difference (SMD) of -0.81.
  • Function improved with exercise, showing a standardized mean difference (SMD) of -0.69.
  • Supervised abdominopelvic core exercise showed more pronounced effects, though based on limited data.

Why it matters

Understanding effective exercise parameters for managing pregnancy-related pelvic girdle pain can enhance treatment strategies, potentially improving patient outcomes in this common condition.

Source

PubMed · PMID 42551620

Published in J Pain. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.